<div id="readability-page-1"><p>Jennison Associates LLC reduced its position in  Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,281,601 shares of the company's stock after selling 763,133 shares during the quarter. Jennison Associates LLC owned approximately 1.35% of Crinetics Pharmaceuticals worth $59,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><p>A number of other hedge funds have also modified their holdings of CRNX. Headlands Technologies LLC bought a new position in shares of  Crinetics Pharmaceuticals in the second quarter worth approximately $30,000.  Farther Finance Advisors LLC lifted its holdings in shares of  Crinetics Pharmaceuticals by 523.7% in the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company's stock worth $35,000 after buying an additional 707 shares in the last quarter.  Raymond James Financial Inc. purchased a new position in shares of  Crinetics Pharmaceuticals in the second quarter worth $45,000.  Covestor Ltd lifted its holdings in shares of  Crinetics Pharmaceuticals by 23,983.3% in the third quarter. Covestor Ltd now owns 1,445 shares of the company's stock worth $60,000 after buying an additional 1,439 shares in the last quarter.  Finally, Abich Financial Wealth Management LLC purchased a new position in shares of  Crinetics Pharmaceuticals in the third quarter worth $68,000. 98.51% of the stock is currently owned by institutional investors. </p><h2>Analysts Set New Price Targets</h2><p>CRNX has been the topic of several research analyst reports. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Crinetics Pharmaceuticals in a report on Monday, April 20th. The Goldman Sachs Group raised shares of Crinetics Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $67.00 target price on the stock in a report on Monday, January 12th. Wall Street Zen downgraded shares of Crinetics Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, March 28th. Morgan Stanley boosted their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the stock an &#34;overweight&#34; rating in a report on Tuesday, January 6th. Finally, Lifesci Capital raised shares of Crinetics Pharmaceuticals to a &#34;strong-buy&#34; rating in a report on Friday, February 13th. One research analyst  has rated the stock with a Strong Buy rating, eight have issued  a Buy rating and one  has assigned  a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $76.75.</p><p><b>View Our Latest Stock Analysis on Crinetics Pharmaceuticals</b></p><h2>Crinetics Pharmaceuticals Stock Up 0.9%</h2><p>Crinetics Pharmaceuticals stock opened at $38.78 on Friday. The company has a market cap of $4.06 billion, a price-to-earnings ratio of -7.85 and a beta of 0.30. The firm's fifty day moving average is $38.52 and its 200 day moving average is $43.91. Crinetics Pharmaceuticals, Inc. has a 52-week low of $25.83 and a 52-week high of $57.99. </p><p>Crinetics Pharmaceuticals (NASDAQ:CRNX - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $0.08. The company had revenue of $6.16 million for the quarter, compared to the consensus estimate of $4.32 million. Crinetics Pharmaceuticals had a negative net margin of 6,046.22% and a negative return on equity of 41.46%. Crinetics Pharmaceuticals's revenue was up NaN% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.88) earnings per share.  On average, equities research analysts anticipate that  Crinetics Pharmaceuticals, Inc. will post -4.95 earnings per share for the current fiscal year. </p><h2>Insider Activity at Crinetics Pharmaceuticals</h2><p>In related news, insider Stephen F. Betz sold 10,612 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $396,570.44. Following the sale, the insider owned 137,101 shares of the company's stock, valued at $5,123,464.37. This represents a 7.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, CEO Richard Scott Struthers sold 21,981 shares of the company's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $37.37, for a total transaction of $821,429.97. Following the sale, the chief executive officer directly owned 404,778 shares in the company, valued at approximately $15,126,553.86. The trade was a 5.15% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 142,380 shares of company stock valued at $5,569,475 over the last quarter. 4.60% of the stock is currently owned by insiders. </p><h2>Crinetics Pharmaceuticals Profile</h2> (Free Report)<p>Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company's proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics' research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.  </p><p>The company's lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Crinetics Pharmaceuticals</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q1JOWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Crinetics Pharmaceuticals Right Now?</h2><p>Before you consider Crinetics Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crinetics Pharmaceuticals wasn't on the list.</p><p>While Crinetics Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRNX

<p>Jennison Associates LLC has reduced its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 37.3%, selling 763,133 shares in the fourth quarter. After the sale, they hold 1,281,601 shares valued at approximately $59.66 million. Other hedge funds have also adjusted their positions in CRNX. Analysts have mixed ratings on the stock, with a current average rating of "Moderate Buy" and a price target of $76.75. Crinetics Pharmaceuticals reported a quarterly loss of $1.29 EPS, beating estimates, with revenue of $6.16 million.</p>

Market Beat

Crinetics Pharmaceuticals

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

ALPS Medical Breakthrough

iShares Global Healthcare

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

SPDR S&P Biotech

VG Health

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Raymond James Financial

Goldman Sachs

Morgan Stanley

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

GS Hldg R

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Jennison Associates LLC Sells 763,133 Shares of Crinetics Pharmaceuticals, Inc. $CRNX